enVVeno Medical Corp
Company Profile
Business description
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Contact
70 Doppler
IrvineCA92618
USAT: +1 949 261-2900
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
37
Stocks News & Analysis
stocks
Goldman Sachs Earnings: Valuations remain stretched
stocks
Major ASX listed miners overvalued
stocks
Undervalued ASX share with pathway to positive cash flow
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,179.90 | 27.40 | -0.30% |
| CAC 40 | 8,258.94 | 54.18 | -0.65% |
| DAX 40 | 25,297.13 | 55.26 | -0.22% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,235.29 | 3.65 | -0.04% |
| HKSE | 26,620.35 | 224.61 | -0.84% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 53,240.77 | 695.40 | -1.29% |
| NZX 50 Index | 13,629.21 | 88.89 | -0.65% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,858.00 | 25.70 | -0.29% |
| SSE Composite Index | 4,120.37 | 18.46 | 0.45% |